XASX
CC5
Market cap20mUSD
Dec 23, Last price
0.02AUD
Name
LBT Innovations Ltd
Chart & performance
Notes
No notes on this company yet
Write a private note on this company, for your eyes only
Profile
LBT Innovations Limited is dedicated to conceiving, advancing, and bringing to market cutting-edge technological solutions for the healthcare and laboratory sectors. The company's operations span various international locations, including Australia, Switzerland, the United States, the United Kingdom, and Germany. Its offerings include MicroStreak, an automated system designed for streaking and inoculating culture plates, and the Automated Plate Assessment System (APAS), a foundational technology that streamlines the screening and interpretation of culture plates. The firm is also actively developing several other innovations: Automated Gram Strain Assessment, intended for the automated interpretation of gram stain image analysis; WoundVue, an AI-powered tool assisting clinicians with the evaluation and care of chronic wounds; Automated Plate Assessment System Pharma, which leverages sophisticated artificial intelligence image analysis algorithms to automatically identify microbial growth in environmental monitoring applications; and specialized devices capable of detecting biofilms within mammalian tissue. Established in 2004, LBT Innovations Limited maintains its headquarters in Adelaide, Australia.
Key people
Non-Executive Chairman of the Board · since 2023
Chief Financial Officer, Company Secretary · since 2020
Peter Bradley
Vice President - Global Business Development · since 2012
Brenton Barnes
Chief Executive Officer, Managing Director, Executive Director · since 2016
Glenn Haifer
Non-Executive Director · since 2017
Daniel Hill
Non-Executive Director · since 2023
Ian Wisenberg
Non-Executive Director · since 2024
IPO date
Jul 31, 2006
Employees
28
Domiciled in
AU
Incorporated in
AU
Valuation
Title AUD in thousands, except ratios and share amounts | FY | FY | FY | FY | FY | FY | FY | FY |
|---|---|---|---|---|---|---|---|---|
| 2024‑06 | 2023‑06 | 2022‑06 | 2021‑06 | 2020‑06 | 2019‑06 | 2018‑06 | 2017‑06 | |
| Income | ||||||||
Revenues | ||||||||
Cost of revenue | ||||||||
Unusual Expense (Income) | ||||||||
NOPBT | ||||||||
NOPBT Margin | ||||||||
Operating Taxes | ||||||||
Tax Rate | ||||||||
NOPAT | ||||||||
Net income | ||||||||
Dividends | ||||||||
Dividend yield | ||||||||
Proceeds from repurchase of equity | ||||||||
BB yield | ||||||||
| Debt | ||||||||
Debt current | ||||||||
Long-term debt | ||||||||
Deferred revenue | ||||||||
Other long-term liabilities | ||||||||
Net debt | ||||||||
| Cash flow | ||||||||
Cash from operating activities | ||||||||
CAPEX | ||||||||
Cash from investing activities | ||||||||
Cash from financing activities | ||||||||
FCF | ||||||||
| Balance | ||||||||
Cash | ||||||||
Long term investments | ||||||||
Excess cash | ||||||||
Stockholders' equity | ||||||||
Invested Capital | ||||||||
ROIC | ||||||||
ROCE | ||||||||
| EV | ||||||||
Common stock shares outstanding | ||||||||
Price | ||||||||
Market cap | ||||||||
EV | ||||||||
EBITDA | ||||||||
EV/EBITDA | ||||||||
Interest | ||||||||
Interest/NOPBT | ||||||||